EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan

Yoshikazu Inoue iD, Takashi Ogura, Arata Azuma iD, Yasuhiro Kondoh iD, Sakae Homma, Kenya Muraishi, Rie Ikeda, Kaori Ochiai, Yukihiko Sugiyama, Toshihiro Nukiwa iD

Advances in Therapy · 2025-02 · 42 (2) · 1075-1093

DOI: 10.1007/s12325-024-03079-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Advances in Therapy, online erschienen am 23.12.2024. Verfasst von Yoshikazu Inoue und 9 weiteren Autor:innen. Beteiligte Einrichtung: Osaka Anti-Tuberculosis Association, Osaka Fukujuji Hospital, Osaka, Japan. giichiyi@me.com. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Indoles, Protein Kinase Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nippon Boehringer Ingelheim Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisIndolesProtein Kinase InhibitorsHumansMaleFemaleAgedProduct Surveillance, PostmarketingJapanProspective StudiesMiddle AgedVital CapacityAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Adverse drug reactionsEffectivenessIdiopathic pulmonary fibrosisNintedanibPost-marketing surveillance studyReal-worldSafetyTolerability

Substanzen

nintedanibIndolesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Osaka Anti-Tuberculosis Association, Osaka Fukujuji Hospital, Osaka, Japan. giichiyi@me.com.
  • Clinical Research Center, NHO Kinki Chuo Chest Medical Center, 1180 Nagasone-Cho, Kita-Ku, Sakai, Osaka, 591-8555, Japan. giichiyi@me.com.
  • Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan.
  • Mihara General Hospital, Saitama, Japan.
  • Nippon Medical School, Tokyo, Japan.
  • Department of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan.

ORCID-Profile: Yoshikazu Inoue, Arata Azuma, Yasuhiro Kondoh, Toshihiro Nukiwa

Förderung

  • Nippon Boehringer Ingelheim Co., Ltd.

Zitieren

APA

Inoue, Y., Ogura, T., Azuma, A., Kondoh, Y., Homma, S., Muraishi, K., Ikeda, R., Ochiai, K., Sugiyama, Y., & Nukiwa, T. (2025). Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan. Advances in Therapy, 42(2), 1075-1093. https://doi.org/10.1007/s12325-024-03079-2

Vancouver

Inoue Y, Ogura T, Azuma A, Kondoh Y, Homma S, Muraishi K, et al. Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan. Advances in Therapy. 2025;42(2):1075-1093. doi:10.1007/s12325-024-03079-2

BibTeX
@article{Inoue2025,
  author = {Inoue, Yoshikazu and Ogura, Takashi and Azuma, Arata and Kondoh, Yasuhiro and Homma, Sakae and Muraishi, Kenya and Ikeda, Rie and Ochiai, Kaori and Sugiyama, Yukihiko and Nukiwa, Toshihiro},
  title = {Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan},
  journal = {Advances in Therapy},
  year = {2025},
  volume = {42},
  number = {2},
  pages = {1075--1093},
  doi = {10.1007/s12325-024-03079-2}
}
Kostenlos starten →